Colonies of iPSCs on a layer of fibroblasts stained with stem cell marker TRA1-60 (red) and nuclear marker DAPI (blue)

Origin Genomics reports initial preclinical data from OG-102, demonstrating prime-editing correction of a pathogenic APC mutation associated with familial adenomatous polyposis (FAP). We achieved 16.2% mutant-allele correction in primary patient-derived fibroblasts, with <1% local sequence disruption. This favorable local editing profile is encouraging as we move toward embryo studies assessing off-target activity and genomic integrity. Our goal is therapeutic germline gene editing: correcting inherited disease mutations at the earliest stages of human development.

Origin Genomics reports initial preclinical data from OG-101, demonstrating what we believe is the first reported prime-editing correction of a pathogenic BRCA1 mutation. We achieved >25% clean correction in a human breast cancer cell model, with 93–96% of corrected reads containing no additional local changes. Our goal is therapeutic germline gene editing: correcting inherited disease mutations at the earliest stages of human development. Next: WGS, iPSCs, and donated research embryos carrying the same mutation under our IRB-approved research program.

The case for therapeutic germline gene editing: correcting disease-causing mutations in human embryos to prevent inherited disease before it begins. At Origin Genomics, we’re taking a safety-first approach, building the evidence needed to understand whether this can be done safely and precisely.

A look inside Origin Genomics and our work to advance therapeutic germline gene editing, from NPR. npr.org/2026/09/29/nx-s1-595…

Origin Genomics works on correcting disease-causing mutations in early embryos, in the United States, under independent IRB oversight. Our research priorities are editing fidelity, reducing mosaicism, and off target analysis in early embryos, with a focus on diseases that have no treatments today. Source: launch release, 19 March 2026. businesswire.com/news/home/2…

Interesting proof-of-concept for multiplex base editing in embryos. That said, we were surprised by the lack of optimization and benchmarking. The study does not explore guide stoichiometry, delivery parameters, RNA stabilization strategies, or next-generation ABE variants designed to improve editing precision and reduce bystander activity. We were also surprised by the comparison against Cas9 rather than against the current generation of adenine base editors. Finally, editing outcomes in MII-stage embryos cannot always be inferred from observations in HEK293 or hESC systems, making developmental context an important variable to consider. At Origin Genomics, we believe these questions are the real frontier. We're building experimental systems to systematically study how editor architecture, delivery, guide design, and developmental context influence editing outcomes in human embryos. The paper demonstrates feasibility. The more interesting question is how much further efficiency and precision can be pushed with systematic optimization.

1. Our IRB-approved research is intended to study the safety of germline gene editors and help create safe germline gene therapy frameworks in the future. 2. 95% of monogenic diseases have no FDA-approved cures, there are millions of real families suffering from passing down genetic diseases to their children. 3. Parents constantly make decisions for their children's health, that is the standard in bioethics. All medication, like gene therapies (e.g. Baby KJ's case) that are given to newborns or infants are consented under this framework. 4. Safe germline gene correction offers the possibility of preventing the passing down of severe genetic diseases generation after generation, that's what makes it highly effective. Thus, more research should be done on its safety and efficacy as we charter into this medical frontier. #bioethics

We believe frontier biotechnologies like germline gene editing must be developed transparently and responsibly. That’s why Origin Genomics publicly shared our IRB summary, which we believe is a first for this field. We hope more companies follow. Long-term public and regulatory trust will not come from secrecy, but from rigor, transparency, and accountability.